Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.4 USD | +14.08% | +19.08% | -27.42% |
05:15pm | JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating | MT |
May. 10 | Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.42% | 649M | |
+5.48% | 109B | |
+11.35% | 105B | |
-0.38% | 22.25B | |
-12.00% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.41% | 16.85B | |
+2.91% | 13.76B | |
+35.77% | 12.46B |
- Stock Market
- Equities
- PRME Stock
- News Prime Medicine, Inc.
- Transcript : Prime Medicine, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 02